Skip to main content
SpringerLink
Log in

Inclisiran as adjunct lipid-lowering therapy for CVD not cost effective

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Kam N, et al. Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis. PharmacoEconomics : 13 Aug 2020. Available from: URL: https://doi.org/10.1007/s40273-020-00948-w

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Inclisiran as adjunct lipid-lowering therapy for CVD not cost effective. PharmacoEcon Outcomes News 860, 22 (2020). https://doi.org/10.1007/s40274-020-7068-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-020-7068-y

Search

Navigation